17.45
price up icon15.41%   2.33
after-market アフターアワーズ: 17.11 -0.34 -1.95%
loading

Cidara Therapeutics Inc (CDTX) 最新ニュース

pulisher
03:12 AM

Cidara: Potential To Change Flu Prophylaxis Landscape With CD388 - Seeking Alpha

03:12 AM
pulisher
11:29 AM

Cidara to raise up to $105 million in private placement - The Pharma Letter

11:29 AM
pulisher
09:13 AM

Cidara Therapeutics Shares Surge 26% on $105 Mln Private Placement - MarketWatch

09:13 AM
pulisher
08:52 AM

Cidara Therapeutics announces $105 million private placement - Investing.com

08:52 AM
pulisher
08:32 AM

Cidara Therapeutics Announces $105 Million Private Placement - GlobeNewswire

08:32 AM
pulisher
08:30 AM

Cidara Therapeutics Secures $105M Private Placement Led by Venrock Healthcare | CDTX Stock News - StockTitan

08:30 AM
pulisher
Nov 19, 2024

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference - GlobeNewswire

Nov 19, 2024
pulisher
Nov 19, 2024

Cidara Therapeutics CEO to Present at Evercore HealthCONx Conference | CDTX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 17, 2024

(CDTX) Technical Data - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Positive Outlook of CDTX FY2024 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 11, 2024

Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 08, 2024

Analysts Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $29.67 - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Guggenheim - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Cidara Therapeutics: Q3 Earnings Snapshot - Houston Chronicle

Nov 08, 2024
pulisher
Nov 07, 2024

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Cidara's Q3 Loss Widens to $16M Despite Strong CD388 Trial Progress and Cash Position | CDTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 06, 2024
pulisher
Oct 31, 2024

Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews

Oct 31, 2024
pulisher
Oct 31, 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire

Oct 31, 2024
pulisher
Oct 30, 2024

How Cidara Got Its Molecule Back - BioProcess Online

Oct 30, 2024
pulisher
Oct 29, 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat

Oct 29, 2024
pulisher
Oct 23, 2024

Cidara Therapeutics, Inc. (CDTX) Stock Price & Chart | Trade Now - Capital.com

Oct 23, 2024
pulisher
Oct 23, 2024

Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat

Oct 22, 2024
pulisher
Oct 16, 2024

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

(CDTX) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 14, 2024

Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 14, 2024
pulisher
Oct 14, 2024

Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 05, 2024

(CDTX) On The My Stocks Page - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 04, 2024

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Oct 04, 2024
pulisher
Oct 02, 2024

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Oct 02, 2024
pulisher
Oct 02, 2024

Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology

Oct 02, 2024
pulisher
Sep 25, 2024

Cidara Therapeutics Announces Two Presentations on - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

How to Take Advantage of moves in (CDTX) - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations

Sep 24, 2024
pulisher
Sep 24, 2024

Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada

Sep 23, 2024
pulisher
Sep 23, 2024

Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara starts Phase 2b trial of influenza drug CD388 - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - StockTitan

Sep 23, 2024
pulisher
Sep 20, 2024

Biotechs investigate ways to adapt to new clinical trial regulation and economic flux - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Cidara Therapeutics expands Scientific Advisory Board By Investing.com - Investing.com Canada

Sep 20, 2024
pulisher
Sep 19, 2024

Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily

Sep 19, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
大文字化:     |  ボリューム (24 時間):